Evidence map›Paper›PMID 42601585›Full record

ArticleInfection2026

Cost effects of using point-of-care multiplex PCR for high consequence infectious diseases suspect cases.

S Metz, R Golbach, F Borgans, M J G T Vehreschild, T Wolf

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

S MetzDepartment of Internal Medicine II, Infectious Diseases, Goethe University Frankfurt, University Hospital, Frankfurt, Frankfurt am Main, Germany. sebastianmetz164@gmail.com.
R GolbachGoethe University Frankfurt, Institute of Biostatistics and Mathematical Modeling, Frankfurt am Main, Germany.
F BorgansDepartment of Internal Medicine II, Infectious Diseases, Goethe University Frankfurt, University Hospital, Frankfurt, Frankfurt am Main, Germany.
M J G T VehreschildDepartment of Internal Medicine II, Infectious Diseases, Goethe University Frankfurt, University Hospital, Frankfurt, Frankfurt am Main, Germany.
T WolfDepartment of Internal Medicine II, Infectious Diseases, Goethe University Frankfurt, University Hospital, Frankfurt, Frankfurt am Main, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHigh-consequence infectious diseases (HCID) are rare in Europe but require rapid evaluation due to the risk of transmission. Suspected cases often involve resource-intensive high-level isolation. Point-of-care multiplex PCR may shorten unnecessary isolation by enabling faster rule-out.

methodsWe developed a decision-analytic model comparing the BioFire

resultsIn the base case deterministic analysis, strategy 1 increased costs by € 406.35 per infected patient and reduced costs by € 2,009.31 per non-infected patient compared to strategy 2. Concerning the PSA, strategy 1 remained more costly for infected patients (mean Δ

conclusionMultiplex PCR increased costs in true HCID cases but reduced costs in non-infected suspects by shortening isolation. Given the very low frequency of true HCID among suspected cases in Europe, overall cost savings appear plausible, depending on local workflows and isolation costs.

Indexed as

High consequences infectious diseases (HCID)High level isolation unit (HLIU)Multiplex PCRPoint of care testing (POCT)

Identifiers

PMID42601585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.